NCT01128322

CKD-828 Primary Hypertension Trial(Dose-selection)

A Randomized, Double-blind, Multi-center, Multi-factorial, Phase 2 Trial to Evaluate the Efficacy and Safety of S-Amlodipine/Telmisartan Combined or Alone and Select Better Dose of CKD-828 in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 430 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their monotherapy components and placebo, in patients with stage I or II essential hypertension(a mean seated cuff diastolic blood pressure \>=95 and \<=115 mmHg).

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	S-Amlodipine, Telmisartan
DRUG	S-Amlodipine
DRUG	Telmisartan
DRUG	Placebo

Timeline

• Start date: 2010-07-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-05-21
• Last updated: 2011-04-26

Locations

26 sites across 1 country: South Korea